Search Results - topoisomerase

3 Results Sort By:
Topoisomerase III (TOP3) Inhibitors as Antiviral and Anticancer Compounds based on Bisacridines
Abstract: Topoisomerase 3B (TOP3B) is the only topoisomerase that can act on RNA as well as DNA. Thus, it is a target of interest for the development of cancer therapies and RNA viral infection therapies. TOP3B is not an essential gene for carcinogenesis, but a subset of cancer cells with pre-existing genome instability are particularly vulnerable to...
Published: 4/8/2024   |   Inventor(s): Yves Pommier, Sourav Saha, Wenjie Wang, Shar-yin Huang
Keywords(s): Bisacridines, CANCER, Pommier, SARS-CoV-2, TOP, TOP3, TOP3 Inhibitor, TOPOISOMERASE, Topoisomerase III, Topoisomerase Inhibitor, viral infection
Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Topoisomerase III (TOP3) Inhibitors and Antiviral Compounds based on Cyanine Dyes
Topoisomerase 3B (TOP3B) is the only topoisomerase that can act on RNA as well as DNA, and thus has been a target of interest for the development of cancer therapies and RNA viral infection therapies. In the context of cancer, TOP3B is not an essential gene, but a subset of cancer cells with pre-existing genome instability are particularly vulnerable...
Published: 4/8/2024   |   Inventor(s): Yves Pommier, Shar-yin Huang, Wenjie Wang, Weidong Wang, Sourav Saha, Tianyi Zhang, Mariano Garcia-Blanco, Pei-Yong Shi, Yuk-Ching Tse-Dinh, Debbie Kennedy-Boone
Keywords(s): CANCER, Cyanine Dye, NIA, Pommier, SARS-CoV-2, TOP, TOP3, TOP3 Inhibitor, TOPOISOMERASE, Topoisomerase III, Topoisomerase Inhibitor, viral infection, Wang
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology
Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments
A suite of nanocarrier technologies that provide targeted drug delivery of hydrophobic and hydrophilic drugs to specific disease sites. Background: Delivery of therapeutic and diagnostic compounds is limited by the lack of efficient carriers to improve in vivo stability, selectivity as well as to reduce immunogenicity. Conventional nanocarrier design...
Published: 9/24/2024   |   Inventor(s): Juntao Luo, Dandan Guo, Changying Shi
Keywords(s): #SUNYresearch, affinity alkylating agent, autoimmune, autoimmune disease, bioactivity, biocompatible, biomaterials, chemical formulation, chemistry, cisplatin, combintorial conjugated dendrimer, dendritic drug delivery, drug delivery component, drug formulation, Featured, graft rejection, hydrophilic drug, hydrophobic drug, immune modulating, immunogenicity inflammation, inflammatory, inflammatory, inflammatory, inflammatory, inflammatory response, inflammatory response, intracellular delivery, methotrexate, moieties, nanocarriers, nanomedicine, nanoparticle, nanoparticle drug delivery, nanoparticle-enhanced delivery, nanotherapy, polyethylene glycol, polymyxin, targeted biologics delivery, targeted delivery, targeted drug delivery, targeted therapeutic delivery, targeting drug, Technologies, therapeutic drug, topoisomerase, vitamin E
Category(s): Technology Classifications > Drug Delivery, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Healthcare, Campus > Upstate Medical University